Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy

Arjun Sarkar, Mohammad Rashid Siddiqui, Richard J. Fantus, Maha Hussain, Joshua A. Halpern, Ashley E. Ross*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We present the case of an 83-year-old man with metastatic prostate cancer who had testosterone levels reading above castration range despite appropriate medical and surgical castration. Mass spectrometry was performed to confirm presence of testosterone, but no testosterone was detected. The elevated testosterone as measured by standard immunoassay was postulated to be secondary to heterophile antibodies in the patient's serum. This report highlights the need for a high index of suspicion for interference in testosterone immunoassays when levels remain mildly elevated. Mass spectrometry may provide a more reliable method by which to detect testosterone concentration prior to escalation of care.

Original languageEnglish (US)
Article number101657
JournalUrology Case Reports
Volume38
DOIs
StatePublished - Sep 2021

Keywords

  • Heterophile antibody
  • Mass spectrometry
  • Prostate cancer
  • Testosterone assay

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy'. Together they form a unique fingerprint.

Cite this